Please select a Capability in order to start your service request.
BD Showcases Solutions and Technologies to Improve Patient Safety Across the Continuum of Care at #EAHP2017Mar 22, 2017
CANNES, March 22, 2017 - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medication technology company, announced today the availability of its new IV Medication Safety Solution, designed to help to measurably prevent IV medication administration errors. This announcement was made at the European Association of Hospital Pharmacists (EAHP) congress, being held in Cannes, France March 22-24.
IV medication errors are a serious health care issue.1 They can occur at any stage of the medication delivery process, from prescription to administration2 and those occurring at the administration stage are the hardest to intercept.3 Their impact depends on the route of administration, type of drug and patient characteristics.4-8 In particular, intravenous (IV) infusions are identified as frequent contributors to medication errors and patient injuries that result from them.9-11 Clinical burden associated with infusion administration errors is suggesting potentially serious consequences for the patient in up to 29 percent of all observed infusions.11-16
BD provides advanced IV medication safety solutions, through helping to standardise drug library protocols with the Alaris™ Editor, to protect the patient with Alaris™ Plus Pumps with Guardrails™ Safety Software, and to evaluate IV medication errors and clinical practice using the Alaris™ CQI Reporter software and clinical services.
To take a step further in patient safety, BD today is launching the Alaris™ Communication Engine Platform, an enterprise IT software platform providing automated centralised management of all connected infusion devices. This system enables remote networked updates to the hospital drug library without interrupting the patient's infusions, collecting rich and actionable continuous quality improvement (CQI) data and centralising infusion pump device management.
The Alaris™ Communication Engine Platform is a key accelerator to BD's IV Medication Safety Solution, demonstrating proven results helping to improve medication errors reduction17-20 and cost associated to such errors18 while providing continuous quality improvement.17-20
"As we continue to provide innovative thinking to address the unmet needs in the area of medication management, BD recognises the growing contributions of connectivity," said Fernand Goldblat, vice president and general manager of Medication Management Solutions Infusion business for BD Europe. "With our IV Medication Safety Solution, BD can assist in creating a safer medication management process for patients while decreasing costs related to preventable adverse events. This addition to our leading Alaris™ technologies portfolio exemplifies our commitment to transform infusion solutions by making them simpler, seamless and connected.
"This latest development, enhances BD's End-to-End IV Safety capabilities within the Medication Management Solutions portfolio, comprised by the following elements:
Where to find BD at EAHPTo learn more about BD's IV Medication Safety Solution and Medication Management solutions portfolio, including Rowa™Dose, visit BD booth #81 and participate in our satellite symposium:
Learn the importance of decreasing preventable errors throughout different stages of the medication management workflow, optimizing efficiency and reducing risk of exposure to hazardous drugs during preparation.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.